Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23502662 | 0.82 | BRS3 (0.31) | — | |
| SCHEMBL24759829 | 0.80 | — | — | |
| SCHEMBL1911598 | 0.79 | ESR1 (0.32) | — | |
| SCHEMBL21024977 | 0.79 | — | — | |
| SCHEMBL15528280 | 0.74 | — | — | |
| SCHEMBL16061663 | 0.71 | — | — | |
| SCHEMBL30238079 | 0.70 | CYP3A4 (0.33) | LMNACYP1A2CYP3A4CYP2C9NFKB1 | |
| SCHEMBL25372657 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL30723640 | 0.70 | — | — | |
| SCHEMBL11212032 | 0.69 | MEN1 (0.34) | MEN1GMNNGABBR2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340592-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2022-10-27 | — | — | US | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | ASTRAZENECA AB (SE) | 2022-06-07 | — | — | US | disclosed |
| EP-3539961-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3539961-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2021-10-06 | — | — | EP | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2021-06-10 | — | — | US | disclosed |
| CN-107873028-B | Polycyclic amide derivatives useful as CDK9 inhibitors | 阿斯利康(瑞典)有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-10717746-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-07-21 | — | — | US | disclosed |
| US-10717746-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-07-21 | — | — | US | disclosed |
| EP-3313838-B1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2019-04-03 | — | — | EP | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-05 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| US-9845331-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-12-19 | — | — | US | disclosed |
| WO-2017001354-A1 | POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS | ASTRAZENECA AB (SE) | 2017-01-05 | — | — | WO | disclosed |
| US-20160376287-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-12-29 | — | — | US | disclosed |
| US-20160376287-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340592-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | MEN1 741/4885GMNN 565/4885GABBR2 2002/4885 |
| US-20210171541-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | MEN1 741/4885GMNN 565/4885GABBR2 2002/4885 |
| US-20160376287-A1 | Chemical Compounds | CDK9, BCL9, BCL9L | MEN1 741/4885GMNN 565/4885GABBR2 2002/4885 |
| US-10717746-B2 | Chemical compounds | CDK9, BCL9, BCL9L | MEN1 741/4885GMNN 565/4885GABBR2 2002/4885 |
| US-20180093998-A1 | CHEMICAL COMPOUNDS | CDK9, BCL9, BCL9L | MEN1 741/4885GMNN 565/4885GABBR2 2002/4885 |
| US-11352369-B2 | Pyridine and pyrimidine derivatives | CDK9, BCL9, CDK19 | MEN1 1266/4885GMNN 748/4885GABBR2 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.